Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes

Abstract

Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100).

Glucose control: Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes, Gla-300 has a more constant and evenly distributed glucose-lowering effect compared with Gla-100, with a duration of action beyond 24 hours and lower within-day and between-day intra-individual variability in blood glucose levels. These benefits translate into predictable and sustained glucose control from a once-daily injection, with potential for fewer hypoglycemia episodes and less weight gain.

Case studies: Case studies are presented to highlight the potential clinical benefits and considerations associated with initiating treatment with Gla-300 in people with type 1 and type 2 diabetes.

Keywords:

• Hypoglycemia
• insulin glargine 300 units/mL
• insulin therapy
• treatment case study

Notes

Transparency

Declaration of funding

The authors indirectly received funding for preparation of this manuscript from Sanofi US Inc.

The contents of this article and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication. The authors took responsibility for the writing of this manuscript, including critical review and editing of each draft, and approval of the submitted version.

Declaration of financial/other relationships

J.S. has disclosed that she was a member of a speakers bureau for AstraZeneca, BI-Lilly, Janssen, Novo Nordisk and Sanofi, served on advisory boards for Ascentia, Novo Nordisk and Sanofi, and served on steering committees for Sanofi. D.K. has disclosed that she was a member of a speakers bureau for AstraZeneca, BI, Dexcom, Janssen, Lilly and Novo Nordisk, served on advisory boards for Dexcom, Janssen, Lilly, Novo Nordisk and Sanofi. L.N. has disclosed that she was a member of a speakers bureau for Janssen, Novo Nordisk, and AstraZeneca.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

The authors received writing/editorial support in the preparation of this manuscript, provided by Matthew Lewis, PhD, of Excerpta Medica, funded by Sanofi US Inc.

Notes

1 SoloSTAR is a registered trade name of Sanofi-Aventis, Paris, France